Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. Patients in the camrelizumab-rivoceranib group reported significantly greater progression-free survival than the sorafenib group. 2. Treatment-related deaths were comparable ...
1. Camrelizumab improved the overall survival and the progression-free survival of esophageal squamous cell carcinoma patients compared to placebo treatment ...
Click to read the study in The Lancet Oncology.
